MOLECULAR TARGETS FOR COLORECTAL CANCER CHEMOPREVENTION

Lead Research Organisation: University of Leeds
Department Name: Leeds Institute of Molecular Medicine

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50

publication icon
Chan AT (2012) Aspirin in the chemoprevention of colorectal neoplasia: an overview. in Cancer prevention research (Philadelphia, Pa.)

 
Description National Awareness and Early Diagnosis Initiative
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Clinical Research Training Fellowship
Amount £218,500 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2011 
End 12/2013
 
Description EME Programme
Amount £1,186,907 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 11/2010 
End 10/2014
 
Description Project grant
Amount £228,454 (GBP)
Funding ID L381 
Organisation Yorkshire Cancer Research 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2015 
End 12/2017
 
Title HT-29-EP4 human CRC cells 
Description stable transfectant of HT-29 human colorectal cancer cell line expressing EP4 receptor 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2007 
Provided To Others? Yes  
Impact unknown 
 
Description AE3-208 
Organisation Ono Pharmaceutical
Country Japan 
Sector Private 
PI Contribution cell studies with this EP4 receptor antagonist
Collaborator Contribution drug supply
Impact pharmacological inhibition of PGE2-EP4 receptor signalling (essential for Oncogene publication)
Start Year 2006
 
Description The anti-colorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid 
Organisation SLA Pharma AG
Country Switzerland 
Sector Private 
PI Contribution I was PI on RCT and my lab has performed work to understand the mechanistic basis of the anti-cancer activity of EPA. This collaboration continued with further post-doc support and supply of EPA for clinical and pre-clinical studies
Collaborator Contribution post-doc support and supply of EPA for clinical and pre-clinical studies
Impact Gut 2010;59:918-25 Phase III RCT Neoplasia 2010;12:618-27 cell biology of EPA activity Br J Pharmacol 2012;166:1724-37 pre-clinical efficacy of EPA against CRC liver metastasis
Start Year 2008
 
Description The anti-colorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid 
Organisation SLA Pharma AG
Country Switzerland 
Sector Private 
PI Contribution I was PI on RCT and my lab has performed work to understand the mechanistic basis of the anti-cancer activity of EPA. This collaboration continued with further post-doc support and supply of EPA for clinical and pre-clinical studies
Collaborator Contribution post-doc support and supply of EPA for clinical and pre-clinical studies
Impact Gut 2010;59:918-25 Phase III RCT Neoplasia 2010;12:618-27 cell biology of EPA activity Br J Pharmacol 2012;166:1724-37 pre-clinical efficacy of EPA against CRC liver metastasis
Start Year 2008
 
Title seAFOod POlyp Prevention Trial 
Description omega-3 fatty acid EPA 
Type Preventative Intervention - Nutrition and Chemoprevention
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2017
Development Status Under active development/distribution
Clinical Trial? Yes
Impact nil yet 
URL http://www.isrctn.com/ISRCTN05926847
 
Description You and your Guts University public showcase 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Primary Audience Public/other audiences
Results and Impact day meeting for public dissemination of University activities

not sure
Year(s) Of Engagement Activity 2008
 
Description local radio 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Primary Audience Media (as a channel to the public)
Results and Impact radio interview 3-5 mins

don't know
Year(s) Of Engagement Activity 2008
 
Description newspaper article 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Primary Audience Media (as a channel to the public)
Results and Impact small article on research area

not sure
Year(s) Of Engagement Activity 2007